1 | 4cc of lidocaïne® | - | - | - | - | [1] 149 149 |
2 | 9060X | - | - | - | - | [2] 13 13, 149 |
3 | Anatomical Landmark-guided Suprascapular Nerve Block | - | - | - | - | [1] 149 149 |
4 | Baclofen | [1] Baclofen Baclofen | [1] D00241
D00241
| [2] GABBR1 GABBR1, GABBR2 💬 | [7] Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | [8] 2 2, 10, 13, 18, 65, 70, 149, 206 |
5 | Balance | [1] Isoxaflutole Isoxaflutole | - | - | - | [5] 6 6, 11, 46, 81, 149 |
6 | Botox | [1] Botulinum toxin type A Botulinum toxin type A | [1] D00783
D00783
| [1] SNAP25 SNAP25 💬 | [2] Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | [7] 2 2, 6, 13, 47, 51, 149, 226 |
7 | Botulinum Toxin | - | - | - | - | [3] 6 6, 13, 149 |
8 | Botulinum toxin A | [1] Botulinum toxin type A Botulinum toxin type A | [1] D00783
D00783
| [1] SNAP25 SNAP25 💬 | [2] Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | [4] 13 13, 51, 149, 226 |
9 | BOTULINUM TOXIN TYPE A | [1] Botulinum toxin type A Botulinum toxin type A | [1] D00783
D00783
| [1] SNAP25 SNAP25 💬 | [2] Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | [10] 2 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
10 | Brivaracetam | [1] Brivaracetam Brivaracetam | [1] D08879
D08879
| [1] SV2A SV2A 💬 | [1] ECM-receptor interaction ECM-receptor interaction 💬 | [2] 149 149, 309 |
11 | Edonerpic | [1] Edonerpic Edonerpic | - | - | - | [1] 149 149 |
12 | FENFLURAMINE | [1] Fenfluramine Fenfluramine | [1] D07945
D07945
| [5] HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | [10] Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | [4] 140 140, 144, 145, 149 |
13 | Gradient | - | - | - | - | [1] 149 149 |
14 | HC-58 | - | - | - | - | [1] 149 149 |
15 | Lacosamide | [1] Lacosamide Lacosamide | [1] D07299
D07299
| [2] SCN3A SCN3A, SCN9A 💬 | [1] Taste transduction Taste transduction 💬 | [4] 2 2, 46, 149, 298 |
16 | Medicinal air | - | - | - | - | [1] 149 149 |
17 | MEOPA | [1] Nitrous oxide Nitrous oxide | [1] D00102
D00102
| - | - | [1] 149 149 |
18 | OnabotulinumtoxinA | [1] Botulinum toxin type A Botulinum toxin type A | [1] D00783
D00783
| [1] SNAP25 SNAP25 💬 | [2] Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | [4] 6 6, 13, 149, 226 |
19 | Onabotulinumtoxina for Injection | [1] Botulinum toxin type A Botulinum toxin type A | [1] D00783
D00783
| [1] SNAP25 SNAP25 💬 | [2] Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | [1] 149 149 |
20 | Oxybate | [1] gamma-Hydroxybutyric acid gamma-Hydroxybutyric acid | - | - | - | [2] 6 6, 149 |
21 | Padsevonil | [1] Padsevonil Padsevonil | [1] D11842
D11842
| [3] SV2A SV2A, SV2B, SV2C 💬 | [1] ECM-receptor interaction ECM-receptor interaction 💬 | [1] 149 149 |
22 | Placebo | - | - | - | - | [28] 3 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
23 | Sodium Oxybate | [2] Sodium oxybate Sodium oxybate, gamma-Hydroxybutyric acid | [1] D05866
D05866
| - | - | [2] 6 6, 149 |
24 | SPM927 | - | - | - | - | [1] 149 149 |
25 | T-817MA | - | - | - | - | [1] 149 149 |
26 | Time delay treatment of botulinum toxin | - | - | - | - | [1] 149 149 |
27 | Triheptanoin | [1] Triheptanoin Triheptanoin | [1] D11465
D11465
| - | - | [10] 2 2, 8, 65, 149, 156, 248, 256, 257, 317, 324 |
28 | Ucb 34714 | - | - | - | - | [2] 149 149, 309 |
29 | Ultrasound-guided Suprascapular Nerve Block | - | - | - | - | [1] 149 149 |
30 | Whole Exome Sequencing | - | - | - | - | [3] 65 65, 120, 149 |